MedTrace Logo

Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke

NCT02460484 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-03-18

No results posted yet for this study

Summary

Autologous human umbilical cord blood (hUCB) stored at Cord Blood Registry will be given to children who have suffered from a Perinatal Arterial Ischemic Stroke. The aim is to determine if hUCB infusion is safe, if late functional outcome is improved, if hUCB treatment improves physiologic response in the child's SSEP \& EEG, and the effect of hUCB infusion in altering anatomic findings on MRI.

Conditions

  • Perinatal Arterial Ischemic Stroke

Interventions

BIOLOGICAL

Autologous Cord Blood Infusion

Intravenous infusion

Sponsors & Collaborators

  • Cord Blood Registry, Inc.

    collaborator INDUSTRY

  • James Baumgartner, MD

    lead OTHER

Principal Investigators

  • James Baumgartner, MD · AdventHealth

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Weeks
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02460484 on ClinicalTrials.gov